| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/27/2013 | WO2013095091A2 Rsv g protein specific antibodies |
| 06/27/2013 | WO2013093707A1 Human growth hormone receptor antagonist antibodies and methods of use thereof |
| 06/27/2013 | WO2013093693A1 Staphylococcus aureus specific antibodies and uses thereof |
| 06/27/2013 | WO2013093629A2 Modular vaccines, methods and compositions related thereto |
| 06/27/2013 | WO2013093524A2 Method for preparing amorphous precipitated protein particles |
| 06/27/2013 | WO2013093379A1 Novel pharmaceutical compositions comprising an antibody which binds the human anti-mullerian hormone receptor type ii |
| 06/27/2013 | WO2013092985A1 Stable compositions for immunising against staphylococcus aureus |
| 06/27/2013 | WO2013092953A1 Hypoallergenic allergen derivatives of pru p 3 for immunotherapy of ige-mediated peach allergy |
| 06/27/2013 | WO2013092875A1 Vaccines against hpv |
| 06/27/2013 | WO2013092605A1 Hypoallergenic variants of phl p 5, the major allergen from phleum pratense |
| 06/27/2013 | WO2013091924A1 Applications of an immune system-released activating agent (israa) |
| 06/27/2013 | WO2013091903A1 Anti-crac channel antibodies |
| 06/27/2013 | WO2013091898A1 Method for producing high yield attenuated salmonella strains |
| 06/27/2013 | WO2013091260A1 Carious tooth vaccine and preparation method |
| 06/27/2013 | WO2013091103A1 Single domain antibodies as inhibitors of pcsk9 |
| 06/27/2013 | WO2013091080A1 Vesicular stomatitis virus for prime boost vaccines |
| 06/27/2013 | WO2013091040A2 Brucella ovis attenuated strain, vaccine composition and use |
| 06/27/2013 | WO2013091004A1 Prevention and treatment of mycobacterium infection |
| 06/27/2013 | WO2013090989A1 Method of treating inflammatory bowel disease |
| 06/27/2013 | WO2013090965A2 Composition |
| 06/27/2013 | WO2013068563A3 Antibody molecules having specificity for human ox40 |
| 06/27/2013 | WO2013048883A3 Anti-erbb3 antibodies and uses thereof |
| 06/27/2013 | WO2013044215A4 Vegf/dll4 binding agents and uses thereof |
| 06/27/2013 | WO2013040564A3 Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof |
| 06/27/2013 | WO2013026054A3 Production of infectious rna viruses in yeast |
| 06/27/2013 | WO2012159754A3 Individualized vaccines for cancer |
| 06/27/2013 | WO2012116225A9 Muc1 based glycolipopeptide vaccine with adjuvant |
| 06/27/2013 | WO2011022727A3 Antibodies against the ectodomain of erbb3 and uses thereof |
| 06/27/2013 | US20130165634 Expression and export of angiogenesis inhibitors as immunofusins |
| 06/27/2013 | US20130164823 Expression System |
| 06/27/2013 | US20130164733 Hepatitis-c virus testing |
| 06/27/2013 | US20130164364 Liposome targeting compounds and related uses |
| 06/27/2013 | US20130164332 Lawsonia vaccine and methods of use thereof |
| 06/27/2013 | US20130164331 Oral vaccination of fish with live attenuated edwardsiella ictaluri vaccines |
| 06/27/2013 | US20130164330 Methods and Compositions for Treatment of Hematologic Cancers |
| 06/27/2013 | US20130164329 Cell-based methods and reagents |
| 06/27/2013 | US20130164328 Methods for enhancing immune response |
| 06/27/2013 | US20130164325 Ceramide-like glycolipid-associated bacterial vaccines and uses thereof |
| 06/27/2013 | US20130164319 Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes |
| 06/27/2013 | US20130164318 Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes |
| 06/27/2013 | US20130164315 Vaccines - Screening Method |
| 06/27/2013 | US20130164314 Cancer peptide vaccine |
| 06/27/2013 | US20130164313 Dna sequence, and recombinant preparation of group 4 major allergens from cereals |
| 06/27/2013 | US20130164311 Composition, preparation, and use of dense chitosan membrane materials |
| 06/27/2013 | US20130164308 Staphylococcus aureus specific antibodies and uses thereof |
| 06/27/2013 | US20130164303 Combination preparation including a cytokine antagonist |
| 06/27/2013 | US20130164302 Immuno-Modulating Compositions for the Treatment of Immune-Mediated Disorders |
| 06/27/2013 | US20130164301 Treatment of diseases linked to pathological kinin formation |
| 06/27/2013 | US20130164298 P. gingivalis antigenic composition |
| 06/27/2013 | US20130164297 Modulation of activity of neurotrophins |
| 06/27/2013 | US20130164296 Excipients for Stabilising Viral Particles, Polypeptides or Biological Material |
| 06/27/2013 | US20130164295 VEGF/DLL4 Binding Agents and Uses Thereof |
| 06/27/2013 | US20130164294 Substance specific to human pd-1 |
| 06/27/2013 | US20130164292 Human Anti-OPGL Neutralizing Antibodies As Selective OPGL Pathway Inhibitors |
| 06/27/2013 | US20130164291 Method of treating inflammatory bowel disease |
| 06/27/2013 | US20130164289 Human cytomegalovirus vaccine |
| 06/27/2013 | US20130164287 Soluble tumor necrosis factor receptor treatment of medical disorders |
| 06/27/2013 | US20130164286 Fc FUSION PROTEINS |
| 06/27/2013 | US20130164284 Compositions and methods to treat bone related disorders |
| 06/27/2013 | US20130164283 Antibody induced cell membrane wounding |
| 06/27/2013 | US20130164282 Treatment of cancer |
| 06/27/2013 | US20130164277 Compositions and methods including B lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin |
| 06/27/2013 | US20130164259 1,4-substituted piperazine derivatives and methods of use thereof |
| 06/27/2013 | US20130164258 Antiviral Compounds Composed of Three Aligned Aryl Moieties to Treat Diseases such as Hepatitis C |
| 06/27/2013 | US20130164256 Immunobinders directed against tnf |
| 06/27/2013 | US20130164255 Immunotherapy for reversing immune suppression |
| 06/27/2013 | US20130164250 Method for production of bioresorbable microparticles, microparticles thus obtained and use thereof |
| 06/27/2013 | US20130164216 Bladder cancer tumor marker, antibody and use thereof |
| 06/27/2013 | US20130164215 Compositions and methods for detecting, diagnosing, and treating cancer |
| 06/27/2013 | US20130164214 Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells |
| 06/27/2013 | CA2858963A1 Vaccines against hpv |
| 06/27/2013 | CA2855894A1 Pseudomonas aeruginosa oprm epitopes for use in diagnostics and therapeutics |
| 06/27/2013 | CA2853656A1 Method of producing high yield attenuated salmonella strains |
| 06/26/2013 | EP2606899A1 High viscosity macromolecluar compositions for treating ocular conditions |
| 06/26/2013 | EP2606070A1 Antibodies for epidermal growth factor receptor 3 (her3) |
| 06/26/2013 | EP2606069A1 Humanized anti-interleukin 3 receptor alpha chain antibodies |
| 06/26/2013 | EP2606068A1 Combined use of fc gamma riib (cd32b) and cd20 - specific antibodies |
| 06/26/2013 | EP2606063A2 Improved antibodies of the class igg4 |
| 06/26/2013 | EP2606047A1 Lipidated immune response modifier compound compositions, formulations, and methods |
| 06/26/2013 | EP2605793A1 Combination therapy of an afucosylated cd20 antibody with an anti-vegf antibody |
| 06/26/2013 | EP2605792A1 Soluble needle arrays for delivery of influenza vaccines |
| 06/26/2013 | EP2605791A2 Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder |
| 06/26/2013 | EP2605788A2 Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases |
| 06/26/2013 | EP2605766A2 Novel combination therapy for the treatment of cancer |
| 06/26/2013 | EP2605764A1 Combination anti - cancer therapy |
| 06/26/2013 | CN1589278B Recombinant allergen with reduced IgE binding but undiminished T-cell antigenicity |
| 06/26/2013 | CN103180730A Compositions and methods of identifying tumor specific neoantigens |
| 06/26/2013 | CN103180432A Process of producing shelf stable probiotic food |
| 06/26/2013 | CN103180346A Glycolipid for treatment of ischemia reperfusion injury |
| 06/26/2013 | CN103180342A Antibodies for the treatment of HIV |
| 06/26/2013 | CN103180341A Monoclonal antibody specific to major neutralizing epitope of influenza h5 hemagglutinin |
| 06/26/2013 | CN103179989A Small liposomes for delivery of immunogen-encoding rna |
| 06/26/2013 | CN103179987A Pharmaceutical composition and method of inhibiting of production or amplifying elimination of p24 protein |
| 06/26/2013 | CN103179986A Use of antibodies against nk1, nk2 and/or nk3 receptors in cancer treatment |
| 06/26/2013 | CN103179985A Antibodies that bind csf1r |
| 06/26/2013 | CN103179984A Pegylated liposomes for delivery of immunogen-encoding RNA |
| 06/26/2013 | CN103179983A 重组亚单位登革病毒疫苗 Dengue virus recombinant subunit vaccines |
| 06/26/2013 | CN103179982A Protein fusion constructs possessing thrombolytic and anticoagulant properties |
| 06/26/2013 | CN103179981A Safe and functional humanized antibodies |
| 06/26/2013 | CN103173470A Preparation of PCV2 ORF2 capsid protein virus-like particles derived from escherichia coli |